Genetic engineering as an outsourced service to pharma and biotech. We create cell lines faster, cheaper, and better than they or our competitors can do.
- Stage Product In Market
- Industry Biotechnology
- Location Philadelphia, PA, USA
- Currency USD
- Founded September 2018
- Employees 10
- Incorporation Type C-corp
- Website xpresscells.com
We provide outsourced gene editing services to researchers in pharma and biotech. We deliver gene-edited cell lines that improve their research. With our superior FAST-HDR process, we save customers time and money over doing the work themselves. We have almost 40 customers and are expanding our distribution internationally. We sell through e-commerce, online promotion, and sales representatives. We continue to expand our product offerings.
Matt Handel has over 25 years in life sciences. A graduate of Princeton and MIT, Matt has worked in product development, business development, and commercial roles at both Merck and Shire. He is an experienced fund-raiser, operations lead, and sits on several Boards. This is his third start-up.
Oscar Perez Leal, MD, has been at Temple University for 15 years, where he conducts research on biochemistry and molecular biology. Oscar is currently a professor in the School of Pharmacy and is an inventor on multiple patents, including ExpressCells’ technology. He has both medical and business degrees.
Connie Davies has a broad background in finance covering many industries. She is Principal of CD Advisory Services, LLC serving startups and development companies in life science. An alumna from Shire, Connie has worked with SaaS and consultancy firms, IT customized technology management, and biotech development companies. She brings a critical eye and optimized approach in business planning and execution.
Principal, TreD Avon Advisors, LLC. & Interim CEO, SwanBio Therapeutics. Chief Commercial Strategy Officer of Sage Therapeutics, Inc. from 2014 to 2019. Between 2004 and 2014, senior operating (P&L) executive with Shire Pharmaceuticals Group. Prior to that, Tom was with J&J. Between 2000 and 2002, Tom served in C-suite roles as part of Claneil Enterprises, Inc. Earned an MBA from Notre Dame and a BS in civil engineering from Lehigh University.
Joined ExpressCells from the MitoCare Center in the Dept. of Pathology, Anatomy and Cell Biology at Thomas Jefferson University. Experience across the spectrum of molecular biology techniques, including primary and immortalized cell culture; plasmid transfection and RNA interference; gene-editing with CRISPR/Cas9; DNA-RNA isolation, characterization, and cloning; and clone validation. PhD from the University of Graz, Austria.
Wendy DiCiccoBoard Director
Board Director of EyePoint Pharmaceuticals and Carmell Therapeutics. Previously served on three public and private boards. Previously COO & CFO of Centinel Spine, President & COO of Camber Spine Technologies, and CFO for several medical device and biotechnology companies, including 12 years at Kensey Nash Corporation. Started her career with Deloitte & Touche. B.S. degree in Accounting from Philadelphia College of Textiles and Science.
Starting a startup?
Join the world's largest startup network for guidance, tools, and fundraising opportunities.